We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.
Customize Consent Preferences
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Always Active
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
No cookies to display.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
No cookies to display.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
No cookies to display.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
No cookies to display.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
N-(Acid-PEG4)-N-bis(PEG4-Propargyl) is a trifunctional PEG linker that combines a t-butyl ester with two terminal alkynes. The alkynes can be applied in copper-click chemistry with azides to form stable triazole linkages with a target molecule, while the acid can be reacted with amines or alcohols to form stable amides or esters.
Detail
N-(Acid-PEG4)-N-bis(PEG4-Propargyl) is a trifunctional PEG linker that combines a t-butyl ester with two terminal alkynes. The alkynes can be applied in copper-click chemistry with azides to form stable triazole linkages with a target molecule, while the acid can be reacted with amines or alcohols to form stable amides or esters.
Other Products
DBCO-PEG4-Desthiobiotin
Product Info
Document
Product Info
DBCO-PEG4-Desthiobiotin is a PEG linker containing a desthiobiotin group and a DBCO functional group. Desthiobiotin is used for affinity-based applications such as pull-down assays or for ligating with streptavidin proteins while DBCO is a click chemistry handle that quickly reacts with azide groups on target molecules. Desthiobiotin is a sulfur-free analogue of biotin which binds streptavidin with slightly less strength than biotin, which provides it with a soft-release characteristic that is useful for in pull-down assays by minimizing co-elution with endogenous biotinylated molecules. The inclusion of a PEG linker in this molecule improves its aqueous solubility.
Document
DBCO-PEG4-Desthiobiotin is a PEG linker containing a desthiobiotin group and a DBCO functional group. Desthiobiotin is used for affinity-based applications such as pull-down assays or for ligating with streptavidin proteins while DBCO is a click chemistry handle that quickly reacts with azide groups on target molecules. Desthiobiotin is a sulfur-free analogue of biotin which binds streptavidin with slightly less strength than biotin, which provides it with a soft-release characteristic that is useful for in pull-down assays by minimizing co-elution with endogenous biotinylated molecules. The inclusion of a PEG linker in this molecule improves its aqueous solubility.
Nucleic acid testing (NAT) is the method of choice for detection and quantification of a wide range of micro organisms. Primerdesign manufactures and supplies high quality quantitative real-time PCR kits for the detection and simultaneous quantification of numerous significant pathogens . A copy number standard curve is provided for quantification and an the internal extraction template (DNA or RNA), controls for the quality of the nucleic acid extraction and eliminates false negative results.
The kit is designed with the broadest possible detection profile to ensure that all clinically relevant strains and subtypes are detected. Target sequences are selected by working with data from key opinion leaders in the field. Multiple sequence alignments and unprecedented real-time PCR expertise in design and validation ensure the best possible kit. Details of the target and priming specificity are included in the individual handbooks above.
Packaged, optimised and ready to use. Expect Better Data.
Primer and probe mix (150 reactions)
Reverse Transcription, target specific primers (RNA genome viruses only)
Copy number standard curve (sufficient for multiple standard curves)
Internal extraction control – Read through VIC channel*
Endogenous control (150 tests)
RNAse/DNAse free water
*alternative fluorophores available on request
The cfDNA Purification Kit (Magnetic Beads) was developed for cell free DNA (cfDNA) enrichment by separating genomic DNA contamination from isolated cfDNA samples.
Many diagnostic technologies for detection of disease signals in cfDNA begin with isolation and purification of DNA from liquid biopsy that include urine, plasma, cerebrospinal fluid. The most widely explored biotechnology is assays used to detect cancer-derived plasma cfDNA. Silica-based magnetic bead cfDNA isolation kits can reliably extract total DNA from plasma, but typically yield a large variation in cfDNA that includes the presence of genomic DNA that often depends on tumor stage, tumor size, or healthy status individuals. Most of the commercial cfDNA isolation kits can’t specifically recover the cfDNA while leaving the high molecular weight genomic DNA behind. The presence of genomic DNA can lead to decreased sensitivity or inconsistent results in downstream applications such as next-generation sequencing (NGS), PCR, QPCR, and digital PCR etc.
Therefore, an additional purification step to enrich cfDNA before downstream methods helps to improve signal from fragments that originate from cancer cells. A proportion of cancer-derived cfDNA fragment signals are below 100 bp and are often not detectable except by qPCR or single-stranded DNA based library preparation for NGS (1, 2, 3). Furthermore only 1% of cancer-derived fragments are found above 400 bp (1, 2). Capture of size-selected fragments between 90-150 bp improved detection of cancer by 2-4 fold (4). Furthermore, TF-bound and protected cfDNA fragments are also being investigated for active cancer-specific signals down to 35-80 bp (5, 6).
This kit uses Dual Solid Phase Reversible Immobilization (SPRI) technology for cfDNA purification. Most Dual SPRI procedures do NOT recover fragments below 100 bp. The kit can be used for the enrichment of cfDNA isolated from liquid biopsies, plasma, serum, and urine. The kit separates cfDNA (50-500 bp) and genomic DNA, and recovers of 90% of the cfDNA without the high molecular weight genomic DNA with high efficiency. Fragments at 500 bp and above may also be retained. Both the 50-500 bp and >500 bp DNA fractions can be used for downstream applications such as single-stranded or double stranded NGS library prep, qPCR, ddPCR, and other methods.
Features
Separation of cfDNA and genomic DNA; Recovery of both types of DNA
Recovery of cfDNA (50-500 bp)
As short as 50 bp can be recovered
Recovery of high molecular weight genomic DNA
Removal of unwanted components and other impurities
Automation friendly
Examples of cfDNA purification. Both cfDNA and genomic DNA can be recovered separately.
The range of recovered small DNA fragments is from 50 to 500 bp. The input DNA are mixtures of sheared small DNA fragments and intact genomic DNA. The ratios of sheared DNA fragments versus genomic DNA are indicated.
Recovery rates of cfDNA and genomic DNA.
Document
Many diagnostic technologies for detection of disease signals in cfDNA begin with isolation and purification of DNA from liquid biopsy that include urine, plasma, cerebrospinal fluid. The most widely explored biotechnology is assays used to detect cancer-derived plasma cfDNA. Silica-based magnetic bead cfDNA isolation kits can reliably extract total DNA from plasma, but typically yield a large variation in cfDNA that includes the presence of genomic DNA that often depends on tumor stage, tumor size, or healthy status individuals. Most of the commercial cfDNA isolation kits can’t specifically recover the cfDNA while leaving the high molecular weight genomic DNA behind. The presence of genomic DNA can lead to decreased sensitivity or inconsistent results in downstream applications such as next-generation sequencing (NGS), PCR, QPCR, and digital PCR etc.